Ignite Creation Date:
2024-05-06 @ 3:57 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02413762
Status:
COMPLETED
Last Update Posted:
2023-06-01
First Post:
2015-04-07
Brief Title:
The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
Sponsor:
Imperial College London Diabetes Centre
Organization:
Imperial College London Diabetes Centre
Study Overview
Official Title:
The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to investigate the potential of the gut hormones GLP-1 PP PYY and the iron regulatory hormone hepcidin as biomarkers for progression to complications in diabetes mellitus
Detailed Description:
Iron overload and mechanisms inducing insulin resistance are reciprocally linked Dietary iron absorption and iron uptake in liver and adipose tissue are regulated through the hormone hepcidin Iron is implicated in microvascular and macrovascular disease pathways and therefore hepcidin may represent a biomarker for progression to complications in type 2 diabetes mellitus
Serum pancreatic polypeptide levels correlate with visceral adiposity and may therefore contribute to the diagnosis of and risk stratification in the metabolic syndrome
Hypothesis
Measuring iron status incretin hormones and serum pancreatic polypeptide will facilitate discrimination of patients at risk of vascular complications of T2DM and clinically significant non-alcoholic fatty liver disease
Statistical analysis
Serumplasma level of hormone under investigation corrected for age sex BMI diabetes duration blood pressure lipid profile smoking status treatment for diabetes hypertension and dyslipidaemia and HbA1c using multinomial logistic regression and Cox regression models
Serum pancreatic polypeptide levels correlate with visceral adiposity and may therefore contribute to the diagnosis of and risk stratification in the metabolic syndrome
Hypothesis
Measuring iron status incretin hormones and serum pancreatic polypeptide will facilitate discrimination of patients at risk of vascular complications of T2DM and clinically significant non-alcoholic fatty liver disease
Statistical analysis
Serumplasma level of hormone under investigation corrected for age sex BMI diabetes duration blood pressure lipid profile smoking status treatment for diabetes hypertension and dyslipidaemia and HbA1c using multinomial logistic regression and Cox regression models
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None